Noteworthy - Pharmaceutical Executive

ADVERTISEMENT

Noteworthy

New Patent-Defense Path for Pharma

October 1, 2014

Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.

The Human Microbiome — Our Body's Secret Weapon

October 1, 2014

New research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.

The Gate Keeper: Dr. David Haslam, Chair of NICE, UK

October 1, 2014

NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.

Dealmaking: Staying Ahead of the Curve

October 1, 2014

Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?

"Sunshine" Goes Live — Despite Incomplete Information

October 1, 2014

The federal Open Payments program has gone live, but biopharma companies continue to be concerned about the lack of context. Jill Wechsler reports.

Crowdfunding: The Open-Source Option Against Capital Crunch

October 1, 2014

Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.

Investing in African Healthcare: Study, Share, Act — and Grow

September 18, 2014

Is sub-Saharan Africa a jewel box of untapped assets for a growth-obsessed big Pharma? Pharm Exec speaks with Steven Adjei, partner of an investment firm focused on opportunities in the region.

Pharm Exec Global Digest: Technology Special

September 4, 2014

A new transatlantic initiative for start-ups, the medical technology 'disconnect', and the latest developments in wearable healthcare technology are covered in the new issue of Pharm Exec Global Digest.

Pharma Battles Hospitals Over Discount Pricing Program

September 3, 2014

Continued growth in a program that provides low-cost drugs to safety-net hospitals has sparked "trench warfare" over which medicines and providers are eligible for the discounts, writes Jill Wechsler.

ADVERTISEMENT

Click here